Moving forward: Respirology supplement on chronic airway inflammation research in China
Moving forward: Respirology supplement on chronic airway inflammation research in China
复制标题
展望未来：中国慢性气道炎症研究的呼吸学补充
DOI：
10.1111/resp.12202
复制
发表时间：
2013-11
期刊：
影响因子：
6.9
通讯作者：
Hua-Hao Shen
中科院分区：
文献类型：
--
作者：
Zhi-Hua Chen;Hua-Hao Shen
我们非常高兴地介绍这个关于慢性气道炎症研究的呼吸学补充，重点是哮喘和慢性阻塞性肺疾病（COPD）。如果没有许多人的贡献，本期的出版是不可能的。WileyBlackwell帮助启动了这个项目，并向中国征集论文。中国编辑委员会由陈教授荣昌,剑Kang鑫周,Chuntao刘和广发证券王提供了一线同行评审过程,我们非常感谢他们的支持。制作编辑蒋莉莉在管理审稿过程和准备出版方面提供了出色的支持，我们非常感谢她。我们最初收到了22份来自中国呼吸内科医生的投稿；经过彻底的同行评议过程，其中7篇，包括两篇评议，被接受发表。接受的原始论文涵盖了哮喘和慢性阻塞性肺病的基础和临床研究，分别有一篇综述专门针对慢性阻塞性肺病和哮喘。在第一篇原创研究论文中，Liang等人发现p38MAPK在臭氧和卵清蛋白联合引发的哮喘中起关键作用，地米松和p38MAPK抑制剂联合治疗可有效减轻肺部炎症，抑制气道重构。这表明p38MAPK可能参与严重哮喘的皮质类固醇不敏感。第二篇研究论文证明了过氧化物酶体增殖物激活受体- γ在人支气管上皮16-HBE细胞对香烟烟雾暴露的气道炎症反应中的关键作用。第三项研究探讨了呼吸道合胞病毒诱导的喘息背后的机制，并证明病毒感染诱导16-HBE细胞中白三烯C4合成酶mRNA表达并增加半胱氨酸白三烯蛋白水平。在接下来的两项临床研究中，第一项研究考察了雾化大剂量布地奈德对儿童哮喘中重度急性加重的影响，而第二项研究则探讨了procaterol联合吸入布地奈德治疗咳嗽变异性哮喘的有效性和安全性。Zhou和Chen的第一篇综述总结了中国COPD的危险因素和干预措施。第二部分综述了2008 - 2012年中国哮喘研究的主要成果。哮喘和慢性阻塞性肺病都是涉及呼吸道慢性炎症的阻塞性气道疾病。这两种慢性气道疾病都很常见，对个人、家庭和社会都有重大影响。全世界有3亿人患有哮喘，患病率在不同国家占人口的1%至18%不等。慢性阻塞性肺病是全世界发病率和死亡率的主要原因，估计到2020年将成为第四大死亡原因。在中国，慢性阻塞性肺病是2010年第三大死因。幸运的是，越来越多的人认识到哮喘和慢性阻塞性肺病的严重性，重要的是，越来越多的临床医生和科学家致力于哮喘和慢性阻塞性肺病的研究。这些努力大大增加了我们对疾病流行、危险因素、控制状况、发病机制和新的预防或治疗策略的认识。在过去十年中，来自中国的哮喘和COPD研究出版物数量大幅增加。在Pubmed检索关键词“asthma, China”或“COPD, China”，分别检索到2672条或1234条结果（截至2013年9月6日）。2000年中国共发表哮喘论文52篇，COPD论文22篇，2012年哮喘论文336篇，COPD论文194篇（图1）。COPD出版物的数量低于哮喘出版物的数量并不奇怪，因为由于疾病的复杂性和与开发适当的动物模型相关的挑战，COPD研究在世界范围内的进展不如哮喘研究。2000年，中国哮喘和慢性阻塞性肺病的出版物总数仅占全球出版物的很小一部分，哮喘和慢性阻塞性肺病分别占1.9%和3.0%。然而，令人鼓舞的是，这两项比率在2012年都增加到了5.6%左右。基于过去十年观察到的上升趋势，我们预计中国的原始呼吸研究在未来几年将继续增加其国际知名度。在中国所有关于慢性气道疾病的研究中，我们想强调以下几项具有重要意义的研究。Zhong等在对年轻学生进行的为期2年的随访研究中发现，一小部分人群（约2.5%）存在无症状气道高反应性，在这一人群中，39.5%的人最终出现了症状性哮喘。这项研究引入了“潜在哮喘”的概念，现在已被广泛接受。我们最近发现了另一种新的哮喘表型，胸闷变异性哮喘，其唯一的表现是胸闷。这些新概念将引领bs_bs_banner
It gives us great pleasure to introduce this Respirology supplement on chronic airway inflammation research, with an emphasis on asthma and chronic obstructive pulmonary disease (COPD). The publication of this issue would not have been possible without the contributions of many people. WileyBlackwell helped to launch the project and sent out a call for papers from China. A Chinese editorial board comprised of Professors Rongchang Chen, Jian Kang, Xin Zhou, Chuntao Liu and Guangfa Wang provided the first-tier peer review process, and we are immensely grateful for their support. Lily Jiang, the production editor, has offered excellent support with managing the review process and preparing the issue for publication, and we are most grateful to her. We originally received 22 submissions from Chinese respirologists; after a thorough peer-review process, seven of these, including two reviews, were accepted for publication. The accepted original papers cover both basic and clinical research into asthma and COPD, with one review each dedicated to COPD and asthma, respectively. In the first original research paper, Liang et al. show that p38MAPK is critically involved in asthma triggered by a combination of ozone and ovalbumin, and that co-treatment of dexamethasone and p38MAPK inhibitor effectively reduced lung inflammation and inhibited airway remodelling. This suggests that p38MAPK is likely to be involved in corticosteroid insensitivity of severe asthma. The second research paper demonstrates a critical role for peroxisome proliferator-activated receptor-gamma in the airway’s inflammatory response to cigarette smoke exposure in human bronchial epithelial 16-HBE cells. The third study examines the mechanisms behind respiratory syncytial virus-induced wheezing, and demonstrates that the virus infection induces mRNA expression of Leukotriene C4 synthase and increases protein levels of cysteinyl leukotrienes in 16-HBE cells. In the following two clinical investigations, the first examines the effects of nebulized high-dose budesonide on moderate-to-severe acute exacerbation of asthma in children, while the second explores the efficacy and safety of procaterol in combination with inhaled budesonide for treatment of cough-variant asthma. The first review by Zhou and Chen summarizes the risk factors and interventions for COPD in China. The second review summarizes the major achievements of asthma research in China between 2008 and 2012. Asthma and COPD are both obstructive airway diseases that involve chronic inflammation of the respiratory tract. These two chronic airway disorders are both very common and have a significant impact on individuals, their families and society. Asthma affects 300 million individuals worldwide, with the prevalence ranging from 1% to 18% of the population in different countries. COPD is a leading cause of morbidity and mortality worldwide, and is estimated to be the fourth leading cause of death by 2020. In China, COPD was the third leading cause of death in 2010. Fortunately, more and more people acknowledge the seriousness of asthma and COPD, and importantly, more and more clinicians and scientists are devoting themselves to research into asthma and COPD. These efforts are significantly increasing our understanding of the disease prevalence, risk factors, control status, pathogenesis and new prevention or treatment strategies. The number of asthma and COPD research publications from China has increased substantially over the last decade. Searching Pubmed for the key words ‘asthma, China’ or ‘COPD, China’, retrieved 2672 or 1234 results respectively (to date of September 6, 2013). A total of 52 asthma papers and 22 COPD papers were published from China in 2000, which has increased to 336 asthma and 194 COPD papers in 2012 (Fig. 1). It is not surprising that the number of COPD publications is lower than the number of asthma publications, as COPD research has progressed less worldwide than asthma research due to the disease complexity and challenges associated with developing appropriate animal models. In 2000, the total numbers of asthma and COPD publications from China made up only a very small part of those worldwide, with 1.9% and 3.0% for asthma and COPD, respectively. However, it is encouraging to see that both of these ratios increased in 2012 to approximately 5.6%. Based on the upward trend observed in the last decade, we expect original respiratory research from China to continue to increase its international profile in the coming years. From all the studies on chronic airway diseases in China, we would like to highlight the following studies of great significance. In a 2-year follow-up study in young students, Zhong et al. found that a small population (around 2.5%) had asymptomatic airway hyperresponsiveness, and in this group, 39.5% finally developed symptomatic asthma. This study introduced the concept of ‘potential asthma’, which has now been widely accepted. We recently identified another new phenotype of asthma, chest tightness variant asthma, whose sole presenting manifestation is chest tightness. These new concepts will lead bs_bs_banner
登录
查看更多内容
影响因子：
9.6
作者：
N. Zhong;Rongchang Chen;Ming Yang;Zhen Ying Wu;Jin Ping Zheng;Yan Fen Li
通讯作者：
N. Zhong;Rongchang Chen;Ming Yang;Zhen Ying Wu;Jin Ping Zheng;Yan Fen Li
影响因子：
6.9
作者：
Yumin Zhou;Rongchang Chen
通讯作者：
Yumin Zhou;Rongchang Chen
影响因子：
6.9
作者：
Chen, Ai-huan;Zeng, Guang-qiao;Zhong, Nanshan
通讯作者：
Zhong, Nanshan
影响因子：
6.9
作者：
Yumin Zhou;Xiao-ping Wang;Xiangyi Zeng;R. Qiu;Jun-fen Xie;Sheng-ming Liu;Jingping Zheng;N. Zhong;P. Ran
通讯作者：
Yumin Zhou;Xiao-ping Wang;Xiangyi Zeng;R. Qiu;Jun-fen Xie;Sheng-ming Liu;Jingping Zheng;N. Zhong;P. Ran
DOI：
10.1016/s0140-6736(13)61097-1
发表时间：
2013-06-08
期刊：
Lancet (London, England)
影响因子：
--
作者：
Yang G;Wang Y;Zeng Y;Gao GF;Liang X;Zhou M;Wan X;Yu S;Jiang Y;Naghavi M;Vos T;Wang H;Lopez AD;Murray CJ
通讯作者：
Murray CJ